{"protocolSection":{"identificationModule":{"nctId":"NCT00153803","orgStudyIdInfo":{"id":"D-0410"},"organization":{"fullName":"Dartmouth-Hitchcock Medical Center","class":"OTHER"},"briefTitle":"Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (D0410)."},"statusModule":{"statusVerifiedDate":"2019-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-05"},"primaryCompletionDateStruct":{"date":"2014-04","type":"ACTUAL"},"completionDateStruct":{"date":"2014-04","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-07","studyFirstSubmitQcDate":"2005-09-07","studyFirstPostDateStruct":{"date":"2005-09-12","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-03-19","resultsFirstSubmitQcDate":"2019-09-04","resultsFirstPostDateStruct":{"date":"2019-09-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-09-04","lastUpdatePostDateStruct":{"date":"2019-09-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Dartmouth-Hitchcock Medical Center","class":"OTHER"},"collaborators":[{"name":"Sanofi","class":"INDUSTRY"},{"name":"Genentech, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a national, randomized, web-based, double-blind study to determine whether erlotinib (Tarceva) compared to placebo improves progression-free survival (PFS) for patients with inoperable, stage III NSCLC following concurrent docetaxel, carboplatin and thoracic radiotherapy. We hypothesize that the introduction of this orally active, well-tolerated agent following concurrent chemoradiation and prior to the emergence of drug resistance will prolong the progression-free survival by 40% (10 months â†’ 14 months).","detailedDescription":"The promising activity of erlotinib as a single agent in advanced refractory NSCLC along with its oral administration and favorable adverse event profile makes this agent an excellent candidate to incorporate into combined modality therapy in the early stages of lung cancer. Based on these data, erlotinib is an attractive novel approach to maintenance therapy in unresectable stage III NSCLC following completion of concomitant chemoradiation. Although, a subset of patients with unresectable stage III NSCLC will be long-term survivors following chemotherapy and thoracic radiation therapy, the vast majority relapse within the first year following therapy and eventually die from chemotherapy refractory disease. We hypothesize that the introduction of an potent tyrosine kinase inhibitor to the epidermal growth factor receptor following effective concomitant chemoradiotherapy with docetaxel and carboplatin will prolong the progression-free survival time for these patients."},"conditionsModule":{"conditions":["Carcinoma, Non-Small-Cell Lung","Non-small Cell Lung Cancer","NSCLC"],"keywords":["Erlotinib","Tarceva","Web based","Stage III NSCLC"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":245,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"Erlotinib (Tarceva) 150mg: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.","interventionNames":["Drug: Erlotinib (tarceva)"]},{"label":"2","type":"PLACEBO_COMPARATOR","description":"Matched Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Erlotinib (tarceva)","description":"Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.","armGroupLabels":["1"]},{"type":"DRUG","name":"Placebo","description":"Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival","description":"Progression Free Survival is defined as time from randomization until documented disease progression or death from any cause. The Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.0) was used to determine disease progression. Irradiated target lesions were considered non-measurable disease. Symptomatic radiographic changes of irradiated non-measurable disease required pathologically confirmation or positive FDG-PET scan 6 months following completion of concurrent chemoradiation to be considered locoregional disease progression. Global deterioration of health status requiring discontinuation of treatment without objective evidence of progression was considered distant disease progression.","timeFrame":"5 years"}],"secondaryOutcomes":[{"measure":"Overall Survival","timeFrame":"From date of randomization until the date of death from any cause, assessed up to 50 months"},{"measure":"Percent of Participants Surviving 3 Years","timeFrame":"36 months"},{"measure":"Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Concurrent Chemoradiation","description":"Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.","timeFrame":"18 months"},{"measure":"Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Erlotinib and Placebo","description":"Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.","timeFrame":"18 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Unresectable, stage IIIA or IIIB NSCLC (measurable disease is not required)\n* No evidence of metastatic disease\n* No prior treatment\n* Adequate organ function\n* Adequate pulmonary function (FEV \\>= 1.0L or predicted FEV \\>0.8L)\n\nExclusion Criteria:\n\n* Metastasis\n* Prior treatment\n* Malignant pleural or pericardial effusion\n* Peripheral neuropathy \\>= grade 2","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"James R Rigas, MD","affiliation":"Norris Cotton Cancer Center","role":"STUDY_CHAIR"}],"locations":[{"facility":"Birmingham Hematology and Oncology Associates, LLC","city":"Birmingham","state":"Alabama","zip":"35235","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Oncology Specialties, P.C.","city":"Huntsville","state":"Alabama","zip":"35801","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Cooper Clinic","city":"Fort Smith","state":"Arkansas","zip":"72913","country":"United States","geoPoint":{"lat":35.38592,"lon":-94.39855}},{"facility":"Genesis Cancer Center","city":"Hot Springs","state":"Arkansas","zip":"71913","country":"United States","geoPoint":{"lat":34.5037,"lon":-93.05518}},{"facility":"Alta Bates Comprehensive Cancer Center","city":"Berkeley","state":"California","zip":"94704","country":"United States","geoPoint":{"lat":37.87159,"lon":-122.27275}},{"facility":"Northstate Cancer Speciality","city":"Redding","state":"California","zip":"96001","country":"United States","geoPoint":{"lat":40.58654,"lon":-122.39168}},{"facility":"Mercy General Hospital","city":"Sacramento","state":"California","zip":"95816","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"St. Francis Hospital Cancer Center","city":"Hartford","state":"Connecticut","zip":"06105","country":"United States","geoPoint":{"lat":41.76371,"lon":-72.68509}},{"facility":"Connecticut Oncology Group","city":"Middletown","state":"Connecticut","zip":"06457","country":"United States","geoPoint":{"lat":41.56232,"lon":-72.65065}},{"facility":"George Bray Cancer Center/New Britain General Hospital","city":"New Britain","state":"Connecticut","zip":"06050","country":"United States","geoPoint":{"lat":41.66121,"lon":-72.77954}},{"facility":"Oncology and Hematology Associates, PC","city":"New London","state":"Connecticut","zip":"06320","country":"United States","geoPoint":{"lat":41.35565,"lon":-72.09952}},{"facility":"Whittingham Cancer Center at Norwalk Hospital","city":"Norwalk","state":"Connecticut","zip":"06856","country":"United States","geoPoint":{"lat":41.1176,"lon":-73.4079}},{"facility":"Hematology/Oncology PC/Carl and Dorothy Bennet Cancer Center","city":"Stamford","state":"Connecticut","zip":"06902","country":"United States","geoPoint":{"lat":41.05343,"lon":-73.53873}},{"facility":"Washington Cancer Institute","city":"Washington D.C.","state":"District of Columbia","zip":"20010","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Pasco Hernando Oncology Associates","city":"Brooksville","state":"Florida","zip":"34613","country":"United States","geoPoint":{"lat":28.55554,"lon":-82.38991}},{"facility":"Florida Cancer Specialists","city":"Fort Myers","state":"Florida","zip":"33901","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Lee Cancer Clinic","city":"Fort Myers","state":"Florida","zip":"33919","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Jupiter Medical Center","city":"Jupiter","state":"Florida","zip":"33458","country":"United States","geoPoint":{"lat":26.93422,"lon":-80.09421}},{"facility":"Cancer Care of North Florida","city":"Lake City","state":"Florida","zip":"32055","country":"United States","geoPoint":{"lat":30.18968,"lon":-82.63929}},{"facility":"Pasco/Hernando Oncology","city":"New Port Richey","state":"Florida","zip":"34652","country":"United States","geoPoint":{"lat":28.24418,"lon":-82.71927}},{"facility":"Mid Florida Oncology","city":"Orange City","state":"Florida","zip":"32763","country":"United States","geoPoint":{"lat":28.94888,"lon":-81.29867}},{"facility":"MD Anderson","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Oncology & Hematology Association of West Broward","city":"Tamarac","state":"Florida","zip":"33321","country":"United States","geoPoint":{"lat":26.21286,"lon":-80.24977}},{"facility":"Palm Beach Cancer Institute","city":"West Palm Beach","state":"Florida","zip":"33410","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"Alexian Brothers Hospital Network","city":"Elk Grove Village","state":"Illinois","zip":"60007","country":"United States","geoPoint":{"lat":42.00392,"lon":-87.97035}},{"facility":"Joliet Hematology Associates","city":"Joliet","state":"Illinois","zip":"60435","country":"United States","geoPoint":{"lat":41.52519,"lon":-88.0834}},{"facility":"Investigative Clinical Research of Indiana LLC","city":"Indianapolis","state":"Indiana","zip":"46254","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Howard Regional Health System","city":"Kokomo","state":"Indiana","zip":"46904","country":"United States","geoPoint":{"lat":40.48643,"lon":-86.1336}},{"facility":"McFarland Clinic","city":"Ames","state":"Iowa","zip":"50010","country":"United States","geoPoint":{"lat":42.03471,"lon":-93.61994}},{"facility":"Kentucky Cancer Clinic","city":"Hazard","state":"Kentucky","zip":"41701","country":"United States","geoPoint":{"lat":37.24954,"lon":-83.19323}},{"facility":"Western Hematology Oncology","city":"Paducah","state":"Kentucky","zip":"42003","country":"United States","geoPoint":{"lat":37.08339,"lon":-88.60005}},{"facility":"Maine Center for Cancer Medicine","city":"Scarborough","state":"Maine","zip":"04074","country":"United States","geoPoint":{"lat":43.57814,"lon":-70.32172}},{"facility":"Sinai Hospital of Baltimore","city":"Baltimore","state":"Maryland","zip":"21215","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Union Memorial Hospital","city":"Baltimore","state":"Maryland","zip":"21218","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Harbor View Cancer Center","city":"Baltimore","state":"Maryland","zip":"21225","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Franklin Square Hospital Center","city":"Baltimore","state":"Maryland","zip":"21237","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Frederick Smith, MD","city":"Chevy Chase","state":"Maryland","zip":"20815","country":"United States","geoPoint":{"lat":39.00287,"lon":-77.07115}},{"facility":"Community Hematology Oncology","city":"Olney","state":"Maryland","zip":"20832","country":"United States","geoPoint":{"lat":39.15316,"lon":-77.06692}},{"facility":"Lahey Clinic Medical Center","city":"Burlington","state":"Massachusetts","zip":"01805","country":"United States","geoPoint":{"lat":42.50482,"lon":-71.19561}},{"facility":"Fallon Clinic Hematology/ Oncology","city":"Worcester","state":"Massachusetts","zip":"01608","country":"United States","geoPoint":{"lat":42.26259,"lon":-71.80229}},{"facility":"Bay Medical Cancer Center","city":"Bay City","state":"Michigan","zip":"48706","country":"United States","geoPoint":{"lat":43.59447,"lon":-83.88886}},{"facility":"Southeast Nebraska Hematology/Oncology","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Methodist Cancer Center","city":"Omaha","state":"Nebraska","zip":"68114","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Nevada Cancer Research Foundation","city":"Las Vegas","state":"Nevada","zip":"89106","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Dartmouth-Hitchcock-Keene","city":"Keene","state":"New Hampshire","zip":"03431","country":"United States","geoPoint":{"lat":42.93369,"lon":-72.27814}},{"facility":"Norris Cotton Cancer Center","city":"Lebanon","state":"New Hampshire","zip":"03756","country":"United States","geoPoint":{"lat":43.64229,"lon":-72.25176}},{"facility":"The Center for Cancer and Hematologic Disease","city":"Cherry Hill","state":"New Jersey","zip":"00000","country":"United States","geoPoint":{"lat":39.93484,"lon":-75.03073}},{"facility":"Sussex County Medical Associates","city":"Newton","state":"New Jersey","zip":"07860","country":"United States","geoPoint":{"lat":41.05815,"lon":-74.75267}},{"facility":"Queens Medical Associates","city":"Fresh Meadows","state":"New York","zip":"11365","country":"United States","geoPoint":{"lat":40.73482,"lon":-73.79347}},{"facility":"Winthrop University Hospital","city":"Mineola","state":"New York","zip":"11501","country":"United States","geoPoint":{"lat":40.74927,"lon":-73.64068}},{"facility":"Hematology Oncology Associates of Rockland, PC","city":"New York","state":"New York","zip":"10956","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Lincoln Hospital","city":"The Bronx","state":"New York","zip":"10451","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Southeastern Medical Oncology Center","city":"Goldsboro","state":"North Carolina","zip":"27534","country":"United States","geoPoint":{"lat":35.38488,"lon":-77.99277}},{"facility":"Aultman Cancer Center","city":"Canton","state":"Ohio","zip":"44710","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"The Cleveland Clinic Foundation Hematology/Med Oncology","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Legacy Good Samaritan","city":"Portland","state":"Oregon","zip":"97201","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"SCOA-SC Onc Assoc","city":"Columbia","state":"South Carolina","zip":"29201","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"VA Department of Hematology/Oncology","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Hope Oncology","city":"Richardson","state":"Texas","zip":"75080","country":"United States","geoPoint":{"lat":32.94818,"lon":-96.72972}},{"facility":"Blood and Cancer Center of East Texas","city":"Tyler","state":"Texas","zip":"75701","country":"United States","geoPoint":{"lat":32.35126,"lon":-95.30106}},{"facility":"Tyler Hematology/Oncology","city":"Tyler","state":"Texas","zip":"75701","country":"United States","geoPoint":{"lat":32.35126,"lon":-95.30106}},{"facility":"Veterans Administration Medical Center","city":"White River Junction","state":"Vermont","zip":"05009","country":"United States","geoPoint":{"lat":43.64896,"lon":-72.31926}},{"facility":"Virginia Oncology Associates Research Program","city":"Newport News","state":"Virginia","zip":"23606","country":"United States","geoPoint":{"lat":36.98038,"lon":-76.42975}},{"facility":"Olympic Hematology/Oncology","city":"Bremerton","state":"Washington","zip":"98310","country":"United States","geoPoint":{"lat":47.56732,"lon":-122.63264}},{"facility":"Morgantown Internal Medicine Group","city":"Morgantown","state":"West Virginia","zip":"26505","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Period 2:Study drug dispensed to only chemoradiation patients who did not experience disease progression, consent withdrawal, death, investigators discretion, or toxicity.","recruitmentDetails":"Period 1: 245 patients were registered \\& randomized. Of those, 10 patients were ineligible due to incorrect stage, withdrawal of consent, inability to meet radiation therapy parameters, and inadequate functional status. The number of participants for each specific reason for ineligibility is unknown. They did not receive any study intervention.","groups":[{"id":"FG000","title":"Tarceva","description":"Tarceva 150mg\n\nErlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy."},{"id":"FG001","title":"Placebo","description":"Matched Placebo\n\nPlacebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy."}],"periods":[{"title":"Concurrent Chemoradiation","milestones":[{"type":"STARTED","comment":"Patients randomized","achievements":[{"groupId":"FG000","numSubjects":"123"},{"groupId":"FG001","numSubjects":"122"}]},{"type":"Received Chemoradiation","achievements":[{"groupId":"FG000","numSubjects":"118"},{"groupId":"FG001","numSubjects":"117"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"118"},{"groupId":"FG001","numSubjects":"117"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}]}]},{"title":"Investigational Drug","milestones":[{"type":"STARTED","comment":"Patients who participated in Period 1","achievements":[{"groupId":"FG000","numSubjects":"118"},{"groupId":"FG001","numSubjects":"117"}]},{"type":"Investigational Drug Dispensed","achievements":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"75"}]},{"type":"COMPLETED","comment":"Received at least one dose","achievements":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"75"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"42"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Tarceva","description":"Tarceva 150mg\n\nErlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy."},{"id":"BG001","title":"Placebo","description":"Matched Placebo\n\nPlacebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"245"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68","lowerLimit":"39","upperLimit":"89"},{"groupId":"BG001","value":"67","lowerLimit":"38","upperLimit":"84"},{"groupId":"BG002","value":"67.5","lowerLimit":"38","upperLimit":"89"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"100"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"145"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"215"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"14"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","description":"Progression Free Survival is defined as time from randomization until documented disease progression or death from any cause. The Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.0) was used to determine disease progression. Irradiated target lesions were considered non-measurable disease. Symptomatic radiographic changes of irradiated non-measurable disease required pathologically confirmation or positive FDG-PET scan 6 months following completion of concurrent chemoradiation to be considered locoregional disease progression. Global deterioration of health status requiring discontinuation of treatment without objective evidence of progression was considered distant disease progression.","populationDescription":"NA = not available; The data cannot be located/provided due to the PI leaving the institution.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"5 years","groups":[{"id":"OG000","title":"Tarceva","description":"Tarceva 150mg\n\nErlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy."},{"id":"OG001","title":"Placebo","description":"Matched Placebo\n\nPlacebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"117"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"NA","upperLimit":"NA","comment":"Data could not be found; The data cannot be located/provided due to the PI leaving the institution."},{"groupId":"OG001","value":"8.1","lowerLimit":"NA","upperLimit":"NA","comment":"Data could not be found; The data cannot be located/provided due to the PI leaving the institution."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.165","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.93","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.65","ciUpperLimit":"1.33"}]},{"type":"SECONDARY","title":"Overall Survival","populationDescription":"NA = not available; The data cannot be located/provided due to the PI leaving the institution.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"From date of randomization until the date of death from any cause, assessed up to 50 months","groups":[{"id":"OG000","title":"Tarceva","description":"Tarceva 150mg\n\nErlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 2 years of therapy."},{"id":"OG001","title":"Placebo","description":"Matched Placebo\n\nPlacebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"117"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","lowerLimit":"NA","upperLimit":"NA","comment":"Data could not be found; The data cannot be located/provided due to the PI leaving the institution."},{"groupId":"OG001","value":"20.3","lowerLimit":"NA","upperLimit":"NA","comment":"Data could not be found; The data cannot be located/provided due to the PI leaving the institution."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.32","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.18","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.85","ciUpperLimit":"1.63"}]},{"type":"SECONDARY","title":"Percent of Participants Surviving 3 Years","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"36 months","groups":[{"id":"OG000","title":"Tarceva","description":"Tarceva 150mg\n\nErlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy."},{"id":"OG001","title":"Placebo","description":"Matched Placebo\n\nPlacebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"117"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"41"}]}]}]},{"type":"SECONDARY","title":"Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Concurrent Chemoradiation","description":"Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"18 months","groups":[{"id":"OG000","title":"Tarceva","description":"Tarceva 150mg\n\nErlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy."},{"id":"OG001","title":"Placebo","description":"Matched Placebo\n\nPlacebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"117"}]}],"classes":[{"title":"Death","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}]}]},{"title":"Disability","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Life-threatening","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]},{"title":"Hospitalization","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"36"}]}]},{"title":"Impairment/damange","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Erlotinib and Placebo","description":"Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"18 months","groups":[{"id":"OG000","title":"Tarceva","description":"Tarceva 150mg\n\nErlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy."},{"id":"OG001","title":"Placebo","description":"Matched Placebo\n\nPlacebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"75"}]}],"classes":[{"title":"Death","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}]}]},{"title":"Disability","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Life-threatening","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Hospitalization (initial or prolonged)","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"23"}]}]},{"title":"Impairment/damange","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"The intent-to-treat population included 235 eligible randomized patients to the erlotinib arm (n = 118) or placebo arm (n = 117); 245 randomized, 10 became ineligible prior to any treatment. Patients were evaluated with a medical history, physical exam, laboratory studies, and toxicity assessment starting at 1st dose, every 4 weeks for 2 months, then every 8-12 weeks until treatment discontinuation. Participants were evaluated, on average, for 6 months, and through study completion up to 3 years","description":"Common Toxicities are reported. Adverse events (Serious, Other Adverse Events) are reporting for only those participants who are included in the intent-to-treat population .This study used the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0 for grading and reporting of toxicities and adverse events.","eventGroups":[{"id":"EG000","title":"Chemoradiation Before Tarceva","deathsNumAffected":26,"deathsNumAtRisk":118,"seriousNumAffected":36,"seriousNumAtRisk":118,"otherNumAffected":12,"otherNumAtRisk":118},{"id":"EG001","title":"Chemoradiation Before Placebo","deathsNumAffected":27,"deathsNumAtRisk":117,"seriousNumAffected":38,"seriousNumAtRisk":117,"otherNumAffected":8,"otherNumAtRisk":117},{"id":"EG002","title":"Tarceva","description":"Tarceva 150mg\n\nErlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.","deathsNumAffected":43,"deathsNumAtRisk":77,"seriousNumAffected":39,"seriousNumAtRisk":77,"otherNumAffected":8,"otherNumAtRisk":77},{"id":"EG003","title":"Placebo","description":"Matched Placebo\n\nPlacebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.","deathsNumAffected":40,"deathsNumAtRisk":75,"seriousNumAffected":23,"seriousNumAtRisk":75,"otherNumAffected":0,"otherNumAtRisk":75}],"seriousEvents":[{"term":"Hemoglobin","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Supraventricular and nodal arrhythmia","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Cardiac Arrhythmia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Cardiac General","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Cardiac General","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Cardiac ischemia/infarction","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Cardiac ischemia/infarction","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hypotension","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Paroxysmal Atrial Tachycardia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Ventricular arrhythmia","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Dehydration","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Dysphagia (difficulty swallowing)","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Esophagitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":118},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Fistula, Esophagus","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Gastritis (including bile reflux gastritis)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Gastrointestinal - Other","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Mucositis/stomatitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Mucositis/stomatitis (functional/symptomatic) Esophagus","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Perforation, GIColon","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"GI/Colon Perforation","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Constitutional Symptoms - Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Fatigue (asthenia, lethargy, malaise)","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Constitutional Symptoms - Fever","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Fever (in the absence of neutropenia, where neutropenia is defined as ANC \\<1.0 x 10eFever (in the absence of neutropenia, where neutropenia is defined as ANC \\<1.0 x 10e9/L)9/L)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Constitutional Symptoms- Other","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Hemorrhage - Respiratory tract NOS","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Hemorrhage, pulmonary/upper respiratory/ Respiratory tract None otherwise specified (NOS)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hemorrhage, GI Lower","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hemorrhage, pulmonary/upper respiratory - Bronchopulmonary","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Hemorrhage, pulmonary/upper respiratory Bronchopulmonary","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hemorrhage, pulmonary/upper respiratory- Lung","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Hemorrhage, pulmonary/upper respiratory- Lung","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Hemorrhage/Bleeding - Other","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pain - Abdomen NOS","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"None otherwise specified (NOW)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pain - Bone","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pain - Joint","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pain - Other","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pain- Chest/thorax","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Allergic Reaction","organSystem":"Immune system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Allergic reaction/hypersensitivity (including drug fever)","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Colitis, Infectious","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"example: Clostridium difficile","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Febrile neutropenia","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection)(ANC \\<1.0 x 10e9/L, fever \\>=38.5 degrees C)","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Infection - Blood","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Infection with normal ANC or Grade 1 or 2 neutrophils Blood","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Infection - Foreign body","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Infection with normal ANC or Grade 1 or 2 neutrophils Foreign body (e.g., graft, implant, prosthesis, stent)","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Infection - Lung","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Infection with normal ANC or Grade 1 or 2 neutrophils Lung (pneumonia)","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Infection - Other","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Infection - Wound","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Infection with normal ANC or Grade 1 or 2 neutrophils Wound","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Fracture","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Musculoskeletal / Soft Tissue - Other","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Musculoskeletal / Soft Tissue - Other","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Cerebrovascular Ischemia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Confusion","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Neurology - Other","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Somnolence/depressed level of consciousness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Obstruction - Ureter","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Dyspnea (shortness of breath)","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":117},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":75}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pleural effusion (non-malignant)","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Pneumonitis/pulmonary infiltrates","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":117},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Upper Respiratory - Other","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":118},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":117},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":77},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"Skin - Other","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Wound complication, non-infectious","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Intra-operative Injury - Other","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Thrombosis/embolism (vascular access-related)","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Thrombosis/thrombus/embolism","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":118},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":117},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Vascular - Other","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]}],"otherEvents":[{"term":"Allergic reaction","organSystem":"Immune system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Allergic reaction/hypersensitivity (including drug fever)","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hemoglobin","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Supraventricular and nodal arrhythmia Atrial fibrillation","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Cardiac General - Other","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Constitutional symptoms - Fever","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Fever (in the absence of neutropenia, where neutropenia is defined as ANC \\<1.0 x 10e9/L)","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Skin - Other","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Dehydration","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Esophagitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Gastrointestinal - Other","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Infection - Other","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Fracture","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Extrapyramidal/involuntary movement/restlessness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pain - Chest/Thorax","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pain - Other","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pneumonitis/pulmonary infiltrates","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Desquamation","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pancreatitis","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pain - Abdomen NOS","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"None otherwise specified (NOS)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Upper respiratory - other","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Embolism","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Thrombosis/ thrombus/ embolism","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":117},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Clinical Research Office","organization":"Dartmouth-Hitchcock Medical Center","email":"Cancer.Research.Nurse@Dartmouth.edu"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}